Immune-related adverse events as clinical biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors.

Immune checkpoint inhibitors (ICI) are an important treatment for metastatic renal cell carcinoma (mRCC). These agents may cause immune-related adverse events (irAEs) and the relationship between irAEs and outcomes is poorly understood.